Results 171 to 180 of about 19,663 (194)

Crizotinib

Reactions Weekly, 2021
  +4 more sources

More on Crizotinib

New England Journal of Medicine, 2011
Dai, Chihara, Ritsuro, Suzuki
openaire   +4 more sources

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

European Journal of Cancer, 2023
Julia Arfi Rouche, Simonin Mathieu, N Cozic   +2 more
exaly  

Crizotinib

Reactions Weekly, 2012
openaire   +1 more source

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

Annals of Oncology, 2019
Sai-Hong Ou, D R Camidge, G I Shapiro
exaly  

Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2

European Journal of Pharmaceutical Sciences, 2020
wenying Shu, Xiaoye Hu
exaly  

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Annals of Oncology, 2014
C H Bartlett, G J Riely, G A Otterson
exaly  

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Annals of Oncology, 2018
Rafal Dziadziuszko, Åslaug Helland, In-Jae Oh   +2 more
exaly  

Crizotinib

Reactions Weekly, 2022
openaire   +1 more source

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer†

Cancer, 2012
Robert C Doebele, Smita Salian-Mehta, Micol S Rothman   +2 more
exaly